British Journal of Cancer · 2003 · 781 citations · 13 references
MedicineImmunologyOncologyCancer ImmunologyInflammationThoracic OncologyCancer Survival AnalysisImmuno-oncology BiomarkersInflammatory BiomarkersLung CancerPrognostic AssessmentTherapy Response AssessmentClinical Grading SystemsLung Cancer StagingNon-small Cell Lung Cancer TreatmentPrognostic Inflammatory BiomarkersSystemic Inflammatory Response Syndrome Criteria
A score based on the combination of the systemic inflammatory response and albumin hazards ratio (HR) 1.70, 95% CI 1.23 - 2.35, P=0.001) was comparable in prognostic value to that based on stage and performance status (HR 1.48, 95% CI 1.12 - 1.95, P=0.006) in patients with inoperable non-small-cell lung cancer. The former is simple to measure and well standardised.
13